Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With LX9851, An Oral Non-incretin Development Candidate, For Obesity And Associated Metabolic Disorders

Lexicon Pharmaceuticals has partnered with Novo Nordisk under an exclusive license agreement for LX9851, an oral candidate targeting obesity and metabolic disorders. Lexicon has received a $10 million milestone payment in 2026 and is eligible for an additional $10 million later this year, with potential total payments reaching up to $1 billion. The Phase 1 study, involving 96 participants, will assess the safety and efficacy of LX9851, with completion expected by Q1 2027.